Key Drivers
- Strong liquidity
- No revenue
- Persistent losses
AIAI Summary
Replimune's valuation is now essentially binary—its market re-rate depends on positive IGNYTE/RP1+Opdivo readouts rather than fundamentals—so investors should prioritize the upcoming RP1 efficacy data, quarterly burn vs. milestones, and any non-dilutive partnership as immediate triggers and be prepared for likely dilution if those catalysts fail. Monitor cash runway, R&D spending, and upcoming IGNYTE timelines closely; a clear positive pivotal signal or sizable upfront deal materially reduces risk, while negative or ambiguous data would sharply compress value.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •No revenue
- •Persistent losses
REPL's balance sheet shows strong liquidity and low leverage, but the absence of revenue, large recurring losses and deep negative operating cash flow signal continued cash burn despite a sizable cash and investment cushion.
Price Behavior
Key Price Behavior Insights:
- •Downtrend momentum
- •Defined support
- •Multi-level resistance
Price is in a clear downtrend after a roughly −19% drop over the last month, finding near-term buying around $6.98–$7.36 but facing resistance at $8.20–$8.64 and higher near $9.70–$10.10, so favor caution and watch for mean-reversion bounces at support.
Rapid ~19% decline over the last month increased short-term downside risk
Sentiment & News
Key News Insights:
- •Large implied upside
- •Active investor outreach
- •Peer valuation focus
Analysts imply ~79.6% upside for Replimune as management steps up investor meetings and peer valuation comparisons, pointing to heightened expectations alongside traditional scrutiny.
Expect increased investor interest and potential short‑term stock momentum, though heightened expectations raise downside risk if results or guidance disappoint
Similar Companies in Healthcare
Other companies in the same sector with AI ratings